InDex Pharmaceuticals Holding (OM:INDEX) - Aandelenkoers, Nieuws & Analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

INDEX Overzicht aandelen

Engages in the research and development of pharmaceuticals for immunological diseases. Meer informatie

INDEX fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De winst is de afgelopen 5 jaar met 2.7% per jaar gegroeid

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 48.5% per jaar dalen.

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

Heeft geen betekenisvolle marktkapitalisatie ( SEK287M )

InDex Pharmaceuticals Holding AB (publ) Concurrenten

ODI Pharma

NGM:ODI

SEK 48.7m

Ziccum

OM:ZICC

SEK 15.9m

Corline Biomedical

OM:CLBIO

SEK 138.0m

AcuCort

NGM:ACUC

SEK 99.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor InDex Pharmaceuticals Holding
Historische aandelenkoersen
Huidige aandelenkoers	SEK 0.55
52 Week Hoogtepunt	SEK 0.93
52 Week Laag	SEK 0.20
Bèta	-0.21
11 maand verandering	35.15%
3 maanden verandering	88.28%
1 Jaar Verandering	-4.55%
33 jaar verandering	-63.84%
5 jaar verandering	-93.87%
Verandering sinds IPO	-92.20%

Recent nieuws en updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Jun 13

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Apr 28

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Jul 11

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Jan 21

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Aug 31

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

Mar 29

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

Feb 04

How Much Are InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Insiders Spending On Buying Shares?

Dec 21

Rendement voor aandeelhouders

	INDEX	SE Pharmaceuticals	SE Markt
7D	1.1%	0.9%	-0.2%
1Y	-4.5%	9.3%	11.8%

Rendement versus industrie: INDEX presteerde slechter dan de Swedish Pharmaceuticals -sector, die het afgelopen jaar een rendement van 9.3 % opleverde.

Rendement versus markt: INDEX presteerde slechter dan Swedish Market, dat het afgelopen jaar een rendement van 11.8 % opleverde.

Prijsvolatiliteit

Is INDEX's price volatile compared to industry and market?
INDEX volatility
INDEX Average Weekly Movement	7.5%
Pharmaceuticals Industry Average Movement	10.7%
Market Average Movement	5.5%
10% most volatile stocks in SE Market	11.3%
10% least volatile stocks in SE Market	3.3%

Stabiele aandelenkoers: De aandelenkoers van INDEX is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van INDEX is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	4	Jenny Sundqvist	www.indexpharma.com

InDex Pharmaceuticals Holding AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van InDex Pharmaceuticals Holding zich tot de beurswaarde?
INDEX fundamentele statistieken
Marktkapitalisatie	SEK 286.59m
Inkomsten(TTM)	-SEK 56.48m
Inkomsten(TTM)	SEK 108.34m

2.7x

P/S-verhouding

-5.1x

Koers/Winstverhouding

Is INDEX overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
INDEX resultatenrekening (TTM)
Inkomsten	SEK 108.34m
Kosten van inkomsten	SEK 4.03m
Brutowinst	SEK 104.31m
Overige uitgaven	SEK 160.79m
Inkomsten	-SEK 56.48m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

Aug 20, 2024

Winst per aandeel (EPS)	-0.11
Brutomarge	96.28%
Nettowinstmarge	-52.13%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde INDEX op de lange termijn?

Bekijk historische prestaties en vergelijking

This company is no longer active

INDEX Overzicht aandelen

Beloningen

Risicoanalyse

InDex Pharmaceuticals Holding AB (publ) Concurrenten

NGM:ODI

SEK 48.7m

OM:ZICC

SEK 15.9m

OM:CLBIO

SEK 138.0m

NGM:ACUC

SEK 99.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

Recent updates

Market Might Still Lack Some Conviction On InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Even After 35% Share Price Boost

Flerie Invest AB entered into an agreement to acquire InDex Pharmaceuticals Holding AB (publ) in a reverse merger transaction.

InDex Pharmaceuticals Holding AB (publ) Approves the Election of Karl Tobieson as Board Member

Further Upside For InDex Pharmaceuticals Holding AB (publ) (STO:INDEX) Shares Could Introduce Price Risks After 26% Bounce

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Index Pharmaceuticals Holding AB (Publ) Announces Board Resignations

InDex Pharmaceuticals Holding AB (publ) Announce Resignation of Johan Giléus as CFO, Effective September 26, 2024

InDex Pharmaceuticals Holding AB (publ) Discontinues the Development of Cobitolimod

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

InDex Pharmaceuticals Holding AB (publ) to Report Q3, 2024 Results on Nov 19, 2024

Third quarter 2023 earnings released: kr0.07 loss per share (vs kr0.006 loss in 3Q 2022)

New major risk - Share price stability

InDex Pharmaceuticals Holding AB (publ) Discontinues Cobitolimod Phase III Program

InDex Pharmaceuticals Holding AB (publ) Announces Composition of the Nomination Committee

InDex Pharmaceuticals Holding AB (Publ) Receives New Patent for Cobitolimod in South Korea

InDex Pharmaceuticals Holding AB (publ) Announces All Patients Needed for the Cobitolimod Dose Selection Milestone Have Completed Induction Study 1 of the Phase III Program Conclude

InDex Pharmaceuticals Holding AB (publ) Announces Positive Results from the Pharmacokinetic (PK) Study

InDex Pharmaceuticals Holding AB (publ) Announces New Formulation Patent for Drug Candidate Cobitolimod Grants by European Patent Office

We're Keeping An Eye On InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Rate

Deputy CEO & Chief Financial Officer recently bought kr66k worth of stock

Price target decreased by 31% to kr1.90

InDex Pharmaceuticals Holding AB (publ) Updates the Timeline of the Phase III Study CONCLUDE with cobitolimod

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Final Results on Apr 12, 2023

InDex Pharmaceuticals Holding AB (publ) to Report Q1, 2023 Results on May 24, 2023

Third quarter 2022 earnings released: kr0.006 loss per share (vs kr0.05 loss in 3Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Appointment of Nomination Committee for the 2023 Annual General Meeting

InDex Pharmaceuticals Holding AB (publ) Appoints Jenny Sundqvist as New CEO, Effective January 1, 2023

We Think InDex Pharmaceuticals Holding (STO:INDEX) Can Afford To Drive Business Growth

Second quarter 2022 earnings released: kr0.04 loss per share (vs kr0.08 loss in 2Q 2021)

InDex Pharmaceuticals Holding AB (publ) Announces Successful Interactions with the Pmda for the Clinical Development of Cobitolimod in Japan

InDex Pharmaceuticals Holding AB (publ) Announces Board Appointments

First quarter 2022 earnings released: kr0.04 loss per share (vs kr0.02 loss in 1Q 2021)

InDex Pharmaceuticals Strengthens the Organization with Eva Arlander as Chief Development Officer and Announces Changes in the Composition of the Management Team

Full year 2021 earnings released: kr0.21 loss per share (vs kr0.24 loss in FY 2020)

InDex Pharmaceuticals Holding AB (publ) Announces CEO Changes

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 23, 2023

Full year 2021 earnings: EPS misses analyst expectations

InDex Pharmaceuticals Holding AB (publ) Announces Resignation of Pernilla Sandwall as Chief Operating Officer

InDex Pharmaceuticals Enrols First Patient in the Pk Study with Cobitolimod

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

InDex Pharmaceuticals Holding AB (publ) Enrolls First Patient in Phase III Study CONCLUDE with Cobitolimod in Ulcerative Colitis

Second quarter 2021 earnings released

InDex Pharmaceuticals Receives FDA Clearance to start the Phase III Study CONCLUDE with Cobitolimod

InDex Pharmaceuticals Holding AB (publ) to Conduct Clinical Pharmacokinetic Study (PK Study) with Cobitolimod in Sweden

InDex Pharmaceuticals Receives First Regulatory Approval to Start the Phase III study CONCLUDE with Cobitolimod

Independent Director Stig Pedersen has left the company

Independent Director Yilmaz Mahshid has left the company

InDex Pharmaceuticals Holding AB (publ) Announces Patient Recruitment for Phase III Study CONCLUDE is Planned to Initiate after Summer

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

Here's Why We're Watching InDex Pharmaceuticals Holding's (STO:INDEX) Cash Burn Situation

InDex Pharmaceuticals Holding AB (Publ) Announces Changes in the Nomination Committee for the 2021 Annual General Meeting

Revenue in line with expectations

Full year 2020 earnings released: kr0.24 loss per share (vs kr1.19 loss in FY 2019)

InDex Pharmaceuticals Holding AB (publ) to Report Fiscal Year 2020 Final Results on Apr 23, 2021

InDex Pharmaceuticals Holding's (STO:INDEX) Shareholders Are Down 24% On Their Investment Over The Past Year.

New 90-day low: kr3.88